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Pdxdc1 modulates prepulse inhibition of acoustic startle in
the mouse
LA Feldcamp1,2, PC Boutros3,4, R Raymond5, PJ Fletcher2,6,7, JN Nobrega5,6,7,8 and AHC Wong1,2,7,8
Current antipsychotic medications used to treat schizophrenia all target the dopamine D2 receptor. Although these drugs have
serious side effects and limited efficacy, no novel molecular targets for schizophrenia treatment have been successfully translated
into new medications. To identify novel potential treatment targets for schizophrenia, we searched for previously unknown
molecular modulators of acoustic prepulse inhibition (PPI), a schizophrenia endophenotype, in the mouse. We examined six inbred
mouse strains that have a range of PPI, and used microarrays to determine which mRNA levels correlated with PPI across these
mouse strains. We examined several brain regions involved in PPI and schizophrenia: hippocampus, striatum, and brainstem, found
a number of transcripts that showed good correlation with PPI level, and confirmed this with real-time quantitative PCR. We then
selected one candidate gene for further study, Pdxdc1 (pyridoxal-dependent decarboxylase domain containing 1), because it is a
putative enzyme that could metabolize catecholamine neurotransmitters, and thus might be a feasible target for new medications.
We determined that Pdxdc1 mRNA and protein are both strongly expressed in the hippocampus and levels of Pdxdc1 are inversely
correlated with PPI across the six mouse strains. Using shRNA packaged in a lentiviral vector, we suppressed Pdxdc1 protein levels
in the hippocampus and increased PPI by 70%. Our results suggest that Pdxdc1 may regulate PPI and could be a good target for
further investigation as a potential treatment for schizophrenia.
Translational Psychiatry (2017) 7, e1125; doi:10.1038/tp.2017.85; published online 9 May 2017
INTRODUCTION
Schizophrenia is the ninth leading cause of years lost to disability
in established market economies,1 yet there have been no new
pharmacological targets for treating schizophrenia since the
discovery of chlorpromazine in 1950.2 All current antipsychotic
medications target the dopamine D2 receptor3,4 and are effective
for reducing hallucinations and delusions,5 but have little benefit
for cognitive impairment or negative symptoms of schizophrenia
such as impaired motivation and social withdrawal.6 This narrow
efficacy means that existing medication treatments do not
significantly improve overall functioning or outcome in
schizophrenia.7,8 The identification of new molecular pathways
for treating schizophrenia is one step towards improving this
situation.
We sought to discover novel potential drug targets for
antipsychotic drug development by searching for mRNA tran-
scripts that modulate the most commonly studied endopheno-
type for schizophrenia: prepulse inhibition of the acoustic startle
reflex (PPI).9 Endophenotypes are heritable ‘intermediate’ pheno-
types that constitute a component of a disease, but which may
not necessarily be part of the diagnosis.10 Current psychiatric
diagnoses are heterogeneous, have complex genetic origins,11
and do not correspond to specific neurobiological pathways,12
which complicates efforts to understand the origins and
pathophysiology of mental illnesses. Endophenotypes can help
resolve the molecular mechanisms underlying specific elements of
complex psychiatric disorders, through human genetic studies of
the endophenotype and animal studies to investigate the
molecular and cellular regulation of the endophenotype.13
PPI is a measure of sensorimotor gating that is typically
measured by exposing an animal to a series of auditory stimuli
loud enough to induce a startle response. When lower-intensity
‘prepulse’ sounds precede a louder ‘pulse’ sound, PPI reduces the
startle response elicited by the second sound.14 Reduced PPI is
manifested as a greater startle response with the same pre-pulse
sound. PPI is reduced in a number of neuropsychiatric disorders
including schizophrenia, obsessive-compulsive disorder and aut-
ism, so is not a diagnosis-specific endophenotype.15 However, PPI
is also reduced in unaffected first-degree relatives of patients with
schizophrenia, and in patients with schizophrenia spectrum
diagnoses such as schizotypal personality disorder, suggesting
that impaired PPI represents a phenotype that is inherited along
with schizophrenia.16 Because PPI can be reliably measured in
both the mouse and in humans, and because sensory gating
deficits are present in schizophrenia and ameliorated by
antipsychotic medication, we reasoned that discovering novel
molecular regulators of PPI in the mouse could provide new
therapeutic targets to treat symptoms of schizophrenia.17
Our strategy was to exploit the variation in PPI levels across
different but closely-related mouse strains to identify mRNA
transcripts that showed variation in expression level correlated
with PPI. A similar approach was used previously to identify
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glyoxalase 1 and glutathione reductase 1 as novel genes regulating
anxiety, by examining anxiety behaviors across different mouse
strains.18 We used expression microarrays for this initial screen and
real-time quantitative PCR to verify the amount of selected
transcripts. Finally, we chose Pdxdc1, which encodes a putative
decarboxylase, for further study because a soluble enzyme with
possible roles in neurotransmitter metabolism is a feasible drug
target. Pdxdc1 mRNA levels were inversely correlated with PPI
level, so we used shRNA to knock down Pdxdc1 levels and saw a
corresponding increase in PPI levels in c57BL/6J mice.
MATERIALS AND METHODS
See Supplementary Material for additional details.
Mice and PPI testing
Six mouse strains were used: C3H/HeJ, BALB/cJ, C57BLKS/J, C57BL/10J,
C57BL/6J and C57L/J (JAX, Bar Harbor, ME, USA) spanning the range of
PPI.19 PND40 mice were housed 6 per cage with a 12 h light/dark cycle
(0700–1900 h), at 21 ± 1 °C, 50–60% humidity, food and water ad libitum.
PPI testing used 120 dB (40 ms) startle (PA), 20 ms prepulses of 75 or 80 dB
(PP), 65 dB background, prepulse-startle latency of 100 ms, and inter-trial
time of 15–30 s. Scores were averaged across three sessions, PPI calculated
as [(PA–PP)/(PA)] × 100, and the mean of 75 and 80 dB trials was used. Six
of 12 mice were tested per strain every other day for 5 days at PND50.
Microarray mRNA transcript analysis
Mice were killed on PND60. Whole striatum, hippocampus, and brainstem
were dissected and snap frozen (−80 °C). RNA was prepared as previously
described using TRIzol reagent (Invitrogen, Mississauga, ON, Canada).20
Affymetrix mouse genome MOE 430 2.0 GeneChip arrays were used to
measure the mRNA levels of434 000 genes using 45 037 probesets. Three
arrays were used per strain, per tissue, with pooled RNA samples.
Hybridization and imaging was performed by The Centre for Applied
Genomics (Toronto, ON, Canada). Transcriptome-wide correlation analysis
between PPI and mRNA relied on Spearman’s rho and linear modeling
analysis, simultaneously fitting 18 arrays per tissue to the model: y= b
+(m) × (PPI), where y is GCRMA pre-processed signal intensity, b the
expression level, PPI levels for a given strain, and m is the slope. Probe sets
were annotated using Affymetrix NetAffx (v27)21 and false discovery rate-
adjusted P-values were calculated. Correlations and q-values were
calculated and candidate genes selected on the combined q-values from
the three brain regions using the formula: − log|q(Hippocampus) × q
(Striatum) × q(Brainstem)|. Microarray data were uploaded to the NCBI
Gene Expression Omnibus (GEO) under the accession number GSE97198.
RT-PCR verification of microarray results
mRNA was reverse-transcribed using the Omniscript RT kit with 5 μg RNA.
Control genes: GAPDH and β-actin (#4308313 and #4352933E TaqMan
Gene Expression Assays, Applied Biosystems, Foster City, CA, USA). Relative
mRNA expression was calculated as: [candidate gene]/[geometric mean of
GAPDH and β-actin CT values].
22 Regression coefficients were calculated
using the Standard Curve Method.23 Array and RT-PCR values were
compared by Spearman correlation, then correlated with PPI scores.
PDXDC1 cloning and Western blots
Human PDXDC1 cDNA (GenBank: BC060871) was cloned into pMCSG53
and expressed in E.coli BL21 DE3. Protein growth and purification were as
previously described.24 Protein was quantified before being loaded onto a
gel then transferred onto nitrocellulose before staining with Rabbit anti-
Pdxdc1 (Abcam, Cambridge, UK, ab83209) or Rabbit anti-beta-actin
(Abcam ab8227) then with Goat anti-rabbit HRP IgG (Abcam, ab6721),
detected and quantified.
In situ hybridization and immunohistochemistry to visualize
anatomy of Pdxdc1 mRNA and protein expression in brain
For in situ hybridization (ISH), PND90 male C57BL/6J mice (n=7) were
anesthetized with Avertin (Sigma-Aldrich, Oakville, ON, Canada) then
transcardially perfused with saline. Brains were removed and frozen.
Twenty micrometer sections were thaw-mounted onto slides.25
Densitometry was performed with MCID 7.0 (InterFocus). Raw optical
density was converted to μCi g− 1 via calibrated standards. Regions were
sampled in 4–5 sections per mouse. For immunohistochemistry (IHC),
PND90 male C57BL/6J mice (n=6) were prepared as above, then perfused
with 4% PFA. Forty micrometer sections were stained with Rabbit anti-
Pdxdc1 (Abcam, ab83209), then biotinylated anti-rabbit IgG conjugated
with ABC-HRP, developed with DAB Peroxidase with nickel and float
mounted. Raw optical density measures were taken as for ISH. ISH and IHC
values were compared in each region to the mean; linear regression and
correlational analyses were performed.
Lentiviral shRNA preparation and brain injection
PND63 male C57BL/6J mice were housed 1 week at The Centre for
Phenogenomics (TCP; Toronto, ON, Canada), 5 mice per cage with 12 h
light-dark cycle (0700–1900), 50–60% humidity, at 21 ± 1 °C, with ad libitum
food and water. Mice were pre-tested for PPI, then injected with virus.
Experiments were conducted as per Figure 1a. GIPZ constructs for mouse
Pdxdc1 shRNAmir V2LMM_63165, V3LMM_453828, non-silencing GIPZ
shRNAmir negative control RHS4346 (Thermo Fisher Scientific, Waltham,
MA, USA) were prepared as per kit directions and sent to SIDNET (The
Hospital for Sick Kids, Toronto, ON, Canada) for packaging with Open
Biosystems TransLenti Viral GIPZ Packaging System (Thermo Fisher
Scientific). Production, concentration and titering were as per the GIPZ
lentiviral product manual. Titers: 1.64 × 109 TU ml− 1 (V2LMM_631165),
1.02 × 109 TU ml− 1 (V3LMM_453828), and 2.1 × 108 TU ml− 1 (RHS4346).
Surgery and infusion. Mice were anesthetized with isoflurane. A 26 ga
non-coring needle delivered 2.5 μl of virus − 2.5 mm from brain surface;
sham surgeries were made without injection. Mice were group housed and
recovered for 2 weeks before testing.
Behavior testing after shRNA injection
Prepulse inhibition. PPI testing was modified from previous reports.26
Testing consisted of: pulse alone (PA), pulse+prepulse (PP81dB, PP73dB
and PP69dB), prepulse alone or no stimulus (NS) (65 dB) with 90 trials
per session. Mice were tested six times, once weekly.
Locomotor activity. Mice were tested 1 h in 120 lux Plexiglas locomotor
boxes with automated beam break recording.
Y-maze and spontaneous alternation. Spontaneous alternation was
measured in 5 min periods as previously described.27
Morris water maze. Morris water maze protocol was modified from
previous reports.28,29 A 1.2 m diameter, 0.5 m deep circular pool filled with
water (23–24 °C), clouded with non-toxic paint. A transparent platform
12 cm diameter, 0.35 m high placed in the centre of the southeast
quadrant of the tank, peripheral optical markers were used. Mice were pre-
tested, then trained for 6 days and probed on day 7.
Statistical analyses
One or two-way analysis of variance (ANOVA) with Tukey HSD or
Bonferroni correction for multiple testing, Student’s paired or unpaired
two-tailed t-tests with or without Welch’s correction using SPSS 15 or 17.
Graphs and some analyses were made using GraphPad Prism 5.0 (La Jolla,
CA, USA).
Tissue analysis after lentiviral shRNA brain injection
IHC was used to determine shRNA localization and protein knockdown.
Mice recovered for 24 h after the last behavioral test, and brains were
collected, prepared, sectioned and stained as previously described. Tissue
from each brain was divided between rabbit anti-tGFP (Pierce Antibodies,
Thermo Fisher Scientific, PA5-22688) and rabbit anti-Pdxdc1 (Abcam,
ab83209). Sections were observed for tGFP distribution and for Pdxdc1
staining density in the tissue. Densitometry was conducted as previously
described. Western blots and real-time RT-PCR were used to quantify
protein and mRNA knockdown.
Western blot. Twenty-five micrograms of total protein was loaded per
well, and blotting was conducted as above, probing for Pdxdc1 and β-
actin. Protein quantity was analyzed with ImageLab (Bio-Rad Laboratories,
Pdxdc1 modulates prepulse inhibition the mouse
LA Feldcamp et al
2
Translational Psychiatry (2017), 1 – 9
Mississauga, ON, Canada, v.1.4): absolute protein levels were quantified
from digital blot image, and Pdxdc1 normalized to β-actin in the same
lane. Normalized values were averaged and compared between treatment
groups. Real-time RT-PCR was conducted as above.
RESULTS
Baseline PPI results
A range of PPI levels across strains was seen, with C3H/HeJ mice
having the highest, and the three C57BL substrains having the
lowest PPI. The overall strain order of PPI is similar to that reported
by Willott et al.,19 with the exception that they reported C57L/J to
have the highest PPI, and C3H/HeJ was the next highest. The
C57BL/10J and C37BLKS/J strains showed very similar and low PPI
in both our data and in Willott et al., but in our data the order is
reversed. Note that in Willott et al., the strain order differed slightly
when different frequencies (pitch) of startle stimuli were used,
although the broad patterns were conserved. One-way ANOVA
showed significant differences in the combined PPI values across
all six strains (Figure 2a; F5,28 = 10.78, Po0.0001, post hoc Tukey’s
HSD), with differences specifically between C3H/HeJ vs Balb/cJ
(*Po0.01), vs C57BL/6J (**Po0.001), vs C57BL/10J (**Po0.001)
and vs C57BLKS/J (**Po0.001). The ASR was lower in C57L/J and
C3H/HeJ compared to the other four strains (F5,30 = 29.73,
Po0.0001, post hoc Tukey’s HSD showing Po0.0001) however,
PPI had no correlation with startle (data not shown).
Microarray results
Linear-modeling analysis of mRNA expression with PPI generated
535 differentially expressed (q40.01) annotated probe sets in
hippocampus, 528 in brainstem and 1149 in striatum. There were
314 probe sets in common between the three tissues (Figure 2b).
Probe sets were chosen for RT-PCR validation based on several
criteria: (1) the q-value; (2) relatively high expression levels; and (3)
the correlation between PPI and transcript level. Transcripts with
multiple probe sets meeting these criteria were given priority as
well as transcripts encoding soluble cytosolic proteins since these
are more feasible drug targets than structural proteins for
example. A selection of high-priority transcripts are shown in
Supplementary Figure S1A. The genes chosen for PCR verification
of RNA levels were Rgs5, Dbndd2, Hist1h2bc, Pdxdc1, and Dnm3. No
Figure 1. Pdxdc1 knockdown increases PPI but not acoustic startle. All figures show percent change in prepulse inhibition (PPI) from week 2 to
5 after surgery. (a) Surgery and testing timeline from arrival at 9 weeks old until death. (b) Three prepulse intensities (PP69, 73, 81) were tested
in every treatment group: one-way ANOVA with each prepulse level showed no significant differences. (c) Combining treatment groups and
prepulse intensities showed a significant increase in PPI after Pdxdc1 knockdown (PPIc refers to combined PPI levels for all prepulse intensities
and treatment groups; shown is the percent change in PPIc after surgery: **P= 0.0025). (d) There was no statistically significant difference in
startle response between groups (shown as percentage of startle before surgery). (e) Longitudinal measurement of startle response from week
1–6. Number of mice per group: sham= 20, -shRNA= 15, V2LMM= 20, V3LMM= 22. ANOVA, analysis of variance.
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significant differences were seen in overall expression levels
across arrays and between groups exposed to PPI testing and control
animals left in their home cages (Supplementary Figure S2).
Real-time RT-PCR verification of mRNA levels
The strongest correlation between mRNA levels measured by PCR
and PPI was for Pdxdc1 in hippocampus (P= 0.03, Figure 2c). There
was also good correlation for Hist1h2bc in brainstem and
hippocampus (P= 0.03, both tissues), and Dbndd2 in brainstem
(P= 0.06) but these data were not corrected for multiple testing
(Supplementary Figure 1b). Pdxdc1 mRNA levels in each strain also
matched their ordering by PPI. These results confirmed that the
microarray analysis was able to identify a gene that was expressed
at high levels in strains of mice with low PPI and vice versa.
Anatomy of Pdxdc1 expression in the brain
DAB IHC was used to visualize Pdxdc1 protein expression and ISH
was used to observe mRNA expression in adult mouse brain slices.
Considerable regional variation was seen in Pdxdc1 expression
(Figure 3a). Thirty-one regions known to have some role in PPI
were sampled in both IHC (Figure 3b, n= 6) and ISH (Figure 3c,
n= 7) stained tissue. Hippocampus (CA1, CA2, CA3, and DG)
showed the highest levels of both Pdxdc1 protein and mRNA.
mRNA and protein levels were consistent for hippocampus,
cingulate, pontine nucleus and dorsal raphe nucleus (o2 s.e.m.
difference between protein and mRNA relative to each respective
mean), while others were quite divergent (42 s.e.m. difference):
frontal associative and orbital cortex, striatum (excluding globus
pallidus), medial septal nucleus, substantia nigra, central nucleus
of inferior colliculus and central cochlear nucleus, anterior part.
For comparison, this analysis was conducted for 73 additional
tissue regions not associated with PPI (not shown). As a group,
brain areas not directly implicated in regulating PPI actually had
slightly higher Pdxdc1 protein levels than those areas implicated
in PPI: PPI area mean= 0.151 ± 0.003 (s.e.m.) vs non-PPI mean=
0.165 ± 0.005 (s.e.m.). This was driven by several regions within
the prefrontal cortex, mesencephalon, hypothalamus and rhom-
benecephalon. However, the overall expression level in non-PPI
areas was more uniform, with few regions deviating more than
2 s.e.m. from the mean of all regions. For mRNA expression, areas
implicated in PPI did not differ substantially from the non-PPI
regions: PPI mean= 53.5 ± 1.37 (s.e.m.) vs non-PPI mean = 53.15 ±
1.97 (s.e.m.).
Overall there was good correlation between mRNA and protein
levels, in both PPI-related and non-PPI regions. PPI-only regions
had Spearman rho= 0.7803 (Po0.0001), r2 = 0.609 (Figure 3d). The
correlation across all regions (Figure 3e) showed Spearman’s
rho = 0.700 (Po0.0001), r2 = 0.576 (not shown). Non-PPI regions
showed Spearman’s rho = 0.701 (Po0.0001), r2 = 0.601 (not
shown). Residuals analysis for all combinations were analyzed,
showing r2 = 0.000 for each.
Pdxdc1 protein is knocked down by shRNA in vivo
The two anti-Pdxdc1 shRNAs (V2 and V3) were effective in
knocking down Pdcxdc1. Infusion of V2, V3 or control shRNA into
Figure 2. Selection of Pdxdc1 as a candidate transcript for regulating
PPI. (a) PPI in six different mouse strains (n= 34 mice total). One-way
ANOVA for PPIc between all groups showed significant differences
(F5,28= 10.78, Po0.0001, post hoc with Tukey’s HSD) between C3H/
HeJ vs Balb/cJ (*Po0.01), vs C57BL/6J (**Po0.001), vs C57BL/10J
(**Po0.001), and vs C57BLKS/J (**Po0.001). PPIc represents the
mean PPI for 75 and 80 dB startle intensities. (b) Venn diagram
showing overlap between brain regions in transcripts that have
levels correlated with PPI. The number of microarray probesets
associated with PPI in each region and in common between regions
are listed. (c) PPI and Pdxdc1 mRNA levels in the hippocampus are
inversely correlated (n= 3 mice per strain per tissue; Spearman’s rho
− 0.8557, P= 0.03). Data shown are from real-time RT-PCR for Pdxdc1
mRNA quantification. The strain order for Pdxdc1 mRNA levels
mirrors the strain order for PPIs in a. ANOVA, analysis of variance;
PPI, prepulse inhibition.
Figure 3. Pdxdc1 mRNA and protein expression in mouse brain. (a) Sample immunohistochemical (IHC) and in situ hybridization (ISH) images
for Pdxdc1 protein and mRNA, respectively, from adult male mice using a visible light microscope. (b) Pdxdc1 mRNA expression in PPI-
associated brain regions measured with ISH (n= 7 mice) and (c) Pdxdc1 protein expression measured with IHC, in naïve male C567BL/6J mice
(n= 6) at 12 weeks of age. DAB (IHC): mean= 0.151± 0.003 (s.e.m.), 2xs.e.m. (+)= 0.157 (− )= 0.144. ISH: mean= 53.5±1.37 (s.e.m.), 2xs.e.m.
(+)= 56.2 (− )= 50.7. Thick dotted lines indicate whole brain averages. Thin dotted lines (+2s.e.m., −2s.e.m.) represent the whole brain
confidence interval (at 2xs.e.m.) for the mean. (d) PPI regions linear regression for DAB and ISH: r2= 0.609, SE of the estimate of
residuals= 0.032. 95% confidence interval (CI): Slope 0.00099 to 0.00183. Correlation analysis Spearman’s rho= 0.706, 95% CI: 0.465 to 0.849,
two-tailed Po0.0001 (32 x,y pairs). (e) Linear regression for all sampled regions. r2= 0.5765, 95% CI: 0.0486 to 0.0836 (105 x,y pairs). Correlation
analysis: Spearman’s rho= 0.7003, 95% CI: 0.584 to 0.789, two-tailed Po0.0001. Aud Ctx, 1° & 2° auditory ctx; BLP, basolateral amygdala;
posterior; BLA.p, basolateral amygdale; anterior; CA1, field CA1 of hippocampus; CA2, field CA2 of hippocampus; CA3, field CA3 of
hippocampus; CIC, central nucleus; inferior colliculus; Cing ctx mid, 1° & 2° cingulate ctx areas; Cing PFC, cingulate ctx area1; CPu, caudate
putamen; DG, dentate gyrus; DRN, dorsal raphe nucleus; FrA Ctx, frontal association ctx; GP, globus pallidus; LVO ctx, lateral/ventral orbital ctx;
MO Ctx, medial orbital ctx; MS, medial septal nucleus; MDL/C/M, mediodorsal thalamic nuclei; NAcC, nucleus accumbens core; NAcS, nucleus
accumbens shell; P/MnR, paramedian and medial raphe nuclei; Pn, pontine nucleus; PnC, caudal pontine reticular nucleus; PPI, prepulse
inhibition; PTg, pedunculotegmental nucleus; SNC, substantia nigra pars compacta; SNR, substantia nigra pars reticulata; Sp5O, spinal
trigeminal tract; Sup Coll, superior colliculus; VCA, anterior ventral cochlear nucleus; Ve muc, vestibular nucleus; VP, ventral pallidum.
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the DG showed tGFP expression ranging from − 1.06 to − 3.80 mm
bregma in both dorsal and ventral DG in all injected mice
(Figure 4a). Pdxdc1 protein was significantly knocked down in all
hippocampal regions by both Pdxdc1 shRNAs (one-way ANOVA
F3,615 = 34.5, Po0.0001). Tukey’s HSD for V2 or V3 vs sham or
control shRNA was significant (Po0.0001) for each comparison
across all regions (Figure 4b). V2 shRNA reduced Pdxdc1 protein in
the DG by 40%, while V3 reduced it by 26%. Pdxdc1 levels were
reduced in other hippocampal areas: CA1 − 16%, CA2 − 30.6%, and
CA3 − 30%. N= 5 brains per region, 6 sections per brain. Significant
differences in expression of Pdxdc1 existed between groups in
CA3 (F3,352 = 109.1, Po0.0001) with post hoc analysis indicating
Pdxdc1 modulates prepulse inhibition the mouse
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differences between V2 and V3 (Po0.001), and sham vs –shRNA
(Po0.05). For DG, significant differences were seen (F552,3 = 192.8,
Po0.001) with post hoc analysis showing differences between V2
and V3, and between control and treated groups (Po0.0001, each
combination).
Western blot confirmed the IHC data, showing a 35.9%
reduction of Pdxdc1 by V3 shRNA (F3,8 = 5.310, P= 0.0263, one-
way ANOVA, Tukey’s HSD, Po0.05), and 31.7% by V2 shRNA
(Figure 4c). Relative protein expression was calculated comparing
Pdxdc1 to β-actin (Figure 4d). Pdxdc1 RNA levels were not
reduced by shRNA, measured by real-time RT-PCR, relative to the
geometric mean of controls GAPDH and β-actin (Figure 4e).
PPI is increased by Pdxdc1 knockdown
PPI was tested 2 weeks after shRNA injection, and testing
continued over 40 days (Figure 1a). The analysis was conducted
on the combined anti-Pdxdc1 shRNA groups in comparison to a
combined control group of both sham and -shRNA groups (from
Figure 1b). PPI levels across all three pre-pulse intensities were
combined into a single measure, PPIc. Pdxdc1 knockdown
produced a significant increase in PPI compared to the control
groups (t= 3.064 df = 205 P= 0.0025, unpaired two-tailed Student’s
t-test, Welch’s correction) (Figure 1c). Conversely, there was no
significant difference in startle reactivity between treatment
groups (F3,76 = 0.547, P= 0.652, one-way ANOVA, Tukey’s HSD;
Figure 1d and e). However, when raw PPI scores are analyzed as a
mean of each treatment group as opposed to percentage change
in each animal from before and after surgery, there are no
significant differences in PPI associated with Pdxdc1 knockdown
(Supplementary Figure S4).
Spontaneous locomotor activity was increased by Pdxdc1
knockdown. The anti-Pdxdc1 shRNA mice had greater horizontal
activity compared to controls during the first 5 min of testing
(Po0.0076, Student’s unpaired two-tailed t-test t= 2.743 df = 78;
Figure 5a and b). The same was true for vertical activity over the
hour of activity observation (Figure 5c): Student’s two-sided t-test
(t= 2.176 d.f. = 76 P= 0.0327). There were no significant behavioral
differences seen in Y-maze or Morris water maze results
(Supplementary Figure S3).
DISCUSSION
To our knowledge, the experiments described above provide the
first evidence that Pdxdc1 may modulate PPI of the acoustic startle
response, a measure of sensorimotor gating in the mouse. We first
identified a number of gene transcripts that could modulate PPI
by measuring brain mRNA levels in six different mouse strains with
a range of PPI. We found ~ 2000 genes with strong correlation
between the amount of mRNA and PPI. Five of the transcripts with
the strongest correlations were quantified with real-time RT-PCR,
and these results were in good agreement with the microarray
data. We focused on Pdxdc1 and knocked down the transcript in
hippocampus with shRNA. Mice with reduced Pdxdc1 protein after
shRNA injection showed increased PPI, consistent with the inverse
correlation between PPI and Pdxdc1 mRNA levels seen on the
microarrays.
We focused on Pdxdc1 in particular because the mRNA and PPI
levels across mouse strains were strongly (inversely) correlated
and because this correlation was consistent across hippocampus,
striatum and brainstem. The function of Pdxdc1 is unknown but
we speculate that it may encode a decarboxylase that is involved
in monoamine neurotransmitter synthesis. This makes Pdxdc1
attractive as a potential drug target because a cytosolic enzyme
could control neurotransmitter levels, and could be accessible to a
small molecule compound. In contrast, genes active during
development, or that encode structural proteins, might be less
effective as a drug target.
One limitation of our experimental design is that we could have
missed other transcripts that modulate PPI because the microarray
we used was based on the genome of B6 mouse strains, and could
thus potentially miss transcripts that are more strongly expressed
in other mouse strains.30 In cases where there is considerable SNP
variability between strains, hybridization artefacts can potentially
skew the data.31 RNA-Seq could be used instead to address this
strain bias. However, we used microarrays only as a starting point
to identify candidate transcripts, and performed a number of
other experiments to verify that Pdxdc1 has an effect on PPI levels.
To investigate the potential role of Pdxdc1 in PPI, we measured
Pdxdc1 expression in brain regions involved in regulating PPI. The
highest levels of Pdxdc1 protein and mRNA were found in the
hippocampus. Lesion and genetic experiments demonstrate that
alterations in the hippocampus can affect PPI.32,33 Furthermore,
there was good correlation between protein and mRNA levels in
the hippocampus, which was not true in some other brain areas.34
The observed differences between Pdxdc1 mRNA and protein
amount in some brain regions is consistent with a dynamic system
modulation function for Pdxdc1 rather than a structural or basic
metabolic function.35,36
To confirm that Pdxdc1 levels can regulate PPI, we used an
engineered lentivirus carrying an shRNA-containing plasmid to
knock down Pdxdc1. PPI increased in mice after Pdxdc1 knock-
down, providing experimental evidence that this protein affects
PPI and could therefore be a potential target for new antipsychotic
medications. The apparent increase in PPI after Pdxdc1 knock-
down was only statistically significant when treatment groups
were combined into knockdown vs control and when the percent
change in PPI in each animal was used as the variable. When raw
PPI scores were analyzed, no significant changes with Pdxdc1
knockdown were seen. This likely is due to the high variability in
PPI scores between animals.
Pdxdc1 protein levels were significantly reduced after shRNA
injection, but mRNA levels were not. It is possible that the shRNA
used may have blocked protein production as an miRNA instead
of an siRNA, or inhibited protein translation instead of promoting
mRNA digestion.37,38 Expression of the tGFP marker was restricted
to the dentate, but Pdxdc1 protein reduction extended more
widely throughout the hippocampus. This discrpancy could be
related to overall hippocampal function and homeostatic shifts in
protein production or inter-individual variability within the tissues
sampled. Further experiments would be required to investigate
these potential explanations.
Pdxdc1 knockdown did not have strong effects on other
behaviors dependent on the hippocampus such as learning and
memory, but did increase locomotor activity. Because locomotion
is often considered a measure of dopamine system output,
Pdxdc1 could be directly or indirectly affecting dopamine
signaling.39 However, decreasing Pdxdc1 levels improved PPI
and increased locomotion, while existing antipsychotic medica-
tions reduce locomotion.3 This suggests that Pdxdc1 is not
modulating PPI through the same mechanism as current
treatments for schizophrenia, but could also be a potential
disadvantage if other rodent behaviors linked to schizophrenia are
similarly affected.
Our interpretation of the behavioral effects of Pdxdc1 knock-
down is hampered by the lack of knowledge about the function of
Pdxdc1. The amino acid homology to existing decarboxylases
suggests that Pdxdc1 may be involved in neurotransmitter
synthesis. Thus, an important next step is to investigate whether
this protein is indeed an enzyme that catalyzes synthesis of
neurotransmitters. Subsequent efforts could be directed at
resolving the structure of this protein with the aim of developing
small molecule inhibitors.
Another obstacle in the quest for better psychiatric drug
treatments is the difficulty in translating disease phenotypes into
animal model assays.40 Decreased PPI is often considered a stable
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Figure 4. Knockdown of Pdxdc1 in vivo with lentiviral shRNA. (a) Pdxdc1-DAB (left column): Two viral shRNAs, V2LMM (V2) and V3LMM (V3),
were used to knock down Pdxdc1 protein in the dentate gyrus of the hippocampus. tGFP-DAB (right column): the DAB stain for tGFP showing
infected areas using V2LMM, V3LMM, or –shRNA viral vectors. Cell bodies and mossy fibers are prominently stained at 4x optical
magnification. The scale bar is 400 μm; n= 5 mice per shRNA. (b) Significant differences in Pdxdc1 expression as measured by relative optical
density (ROD) were seen between anti-Pdxdc1 treated groups and controls (n= 5 mice per group). One-way ANOVA for Pdxdc1 quantity was
performed within each tissue region for each treatment group with the Tukey HSD post hoc test. CA1 showed a significant difference (ANOVA
F3,615= 34.50, Po0.0001) with post hoc analysis differences between V2 vs sham, V2 vs –shRNA, V3 vs sham, and V3 vs –shRNA groups
(***Po0.0001 each comparison). CA2 had significant differences between groups (ANOVA F3,215= 61.75, Po0.0001), and post hoc analysis
showed highly significant differences (***Po0.0001, all comparisons listed: V2 vs sham, V2 vs –shRNA, V3 vs sham, and V3 vs –shRNA groups).
CA3 groups were significantly different (ANOVA F3,352= 109.1, Po0.0001) with post hoc analysis showing differences between V2 vs V3
(**Po0.001), V2 vs sham (***Po0.0001), V2 vs –shRNA (Po0.0001), V3 vs sham (Po0.0001), V3 vs –shRNA (Po0.0001) and between sham vs
–shRNA (Po0.05). (c) Pdxdc1 protein levels in dorsal hippocampus normalized to β-actin, showing a significant decrease with the V3LMM
shRNA; mean ± s.e.m., *Po0.05. (d) Pdxdc1 protein from dorsal hippocampus shown on representative Western blot; Pdxdc1 (top) and β-
actin (bottom) for all treatment groups, 2 lanes for each treatment and 3 lanes sham (n= 4–5 mice per treatment group). (e) Pdxdc1 mRNA
expression between the four treatment groups, normalized to housekeeping genes. No significant differences were seen between the groups.
Data are shown as mean± s.e.m..
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trait endophenotype in schizophrenia spectrum disorders and in
unaffected relatives.10 PPI is also interpreted as a state marker for
psychosis—its restoration in animal models by antipsychotic
medications41 is considered a proxy for the acute reduction of
psychotic symptoms in patients.42 In the work described here, we
have intentionally applied both of these conceptualizations of PPI.
By using differences in PPI across genetically different mouse
strains to identify mRNA transcripts regulating PPI, we are
explicitly treating PPI as a stable genetically-influenced trait. In
contrast, by knocking down Pdxdc1 mRNA with shRNA, and
hypothesizing that this should increase PPI, we are making the
assumption that PPI can be dynamically regulated and that this
could point to antipsychotic-like effects. It would be helpful to
have additional animal behavior or biochemical assays with which
to predict antipsychotic effects in human patients.40
Nevertheless, the results presented here suggest that Pdxdc1
may be a novel modulator of PPI, the most well-known behavioral
endophenotype for schizophrenia. Further investigations into the
function of Pdxdc1 and the effects of inhibiting Pdxdc1 would be
helpful. Because Pdxdc1 is a cytosolic protein with putative
catalytic functions that could dynamically modulate neurotrans-
mitter levels, it is an attractive potential target for new
antipsychotic medications for treating schizophrenia.
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